Historical Valuation
ALX Oncology Holdings Inc (ALXO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.67. The fair price of ALX Oncology Holdings Inc (ALXO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.24
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ALX Oncology Holdings Inc (ALXO) has a current Price-to-Book (P/B) ratio of 1.38. Compared to its 3-year average P/B ratio of 1.52 , the current P/B ratio is approximately -9.45% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about -43.25% higher. ALX Oncology Holdings Inc (ALXO) has a Forward Free Cash Flow (FCF) yield of approximately -156.26%. Compared to its 3-year average FCF yield of -122.72%, the current FCF yield is approximately 27.34% lower. Relative to its 5-year average FCF yield of -77.25% , the current FCF yield is about 102.29% lower.
P/B
Median3y
1.52
Median5y
2.42
FCF Yield
Median3y
-122.72
Median5y
-77.25
Competitors Valuation Multiple
AI Analysis for ALXO
The average P/S ratio for ALXO competitors is 1.41, providing a benchmark for relative valuation. ALX Oncology Holdings Inc Corp (ALXO.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ALXO
1Y
3Y
5Y
Market capitalization of ALXO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ALXO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ALXO currently overvalued or undervalued?
ALX Oncology Holdings Inc (ALXO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.67. The fair price of ALX Oncology Holdings Inc (ALXO) is between NaN to NaN according to relative valuation methord.
What is ALX Oncology Holdings Inc (ALXO) fair value?
ALXO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ALX Oncology Holdings Inc (ALXO) is between NaN to NaN according to relative valuation methord.
How does ALXO's valuation metrics compare to the industry average?
The average P/S ratio for ALXO's competitors is 1.41, providing a benchmark for relative valuation. ALX Oncology Holdings Inc Corp (ALXO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for ALX Oncology Holdings Inc (ALXO) as of Jan 09 2026?
As of Jan 09 2026, ALX Oncology Holdings Inc (ALXO) has a P/B ratio of 1.38. This indicates that the market values ALXO at 1.38 times its book value.
What is the current FCF Yield for ALX Oncology Holdings Inc (ALXO) as of Jan 09 2026?
As of Jan 09 2026, ALX Oncology Holdings Inc (ALXO) has a FCF Yield of -156.26%. This means that for every dollar of ALX Oncology Holdings Inc’s market capitalization, the company generates -156.26 cents in free cash flow.
What is the current Forward P/E ratio for ALX Oncology Holdings Inc (ALXO) as of Jan 09 2026?
As of Jan 09 2026, ALX Oncology Holdings Inc (ALXO) has a Forward P/E ratio of -0.92. This means the market is willing to pay $-0.92 for every dollar of ALX Oncology Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ALX Oncology Holdings Inc (ALXO) as of Jan 09 2026?
As of Jan 09 2026, ALX Oncology Holdings Inc (ALXO) has a Forward P/S ratio of 0.00. This means the market is valuing ALXO at $0.00 for every dollar of expected revenue over the next 12 months.